



August 8, 2022

**BSE Limited**  
Phiroze Jeejeebhoy Towers,  
Dalal Street, Mumbai – 400 001  
Scrip code: 532531

**The National Stock Exchange of India Limited**  
Exchange Plaza, Bandra-Kurla Complex  
Bandra (E) Mumbai - 400 051  
Scrip code: STAR

Dear Madam/ Sir,

**Sub: Press Release**

Please find attached Press Release issued by the Company titled:

**“Strides announces successful completion of US FDA inspection at its Singapore facility”**

Thanks & Regards,  
For **Strides Pharma Science Limited,**

**Manjula** Digitally signed  
by Manjula R  
R Date: 2022.08.08  
19:26:37 +05'30'

**Manjula Ramamurthy**  
**Company Secretary**

Encl. As above

**Strides Pharma Science Limited**

CIN: L24230MH1990PLC057062

Corp Off: Strides House, Bilekahalli, Bannerghatta Road, Bengaluru - 560 076, India | Tel: +91 80 6784 0000 Fax: +91 80 6784 0700

Regd Off: 201, Devavrata, Sector 17, Vashi, Navi Mumbai – 400 703, India | Tel: +91 22 2789 2924 / 3199 Fax: +91 22 2789 2942

corpcomm@strides.com, www.strides.com

## Strides announces successful completion of US FDA inspection at its Singapore facility

### *Inspection completed with Zero 483 observations*

**Bengaluru, August 8, 2022** – Strides Pharma Science Limited (Strides) today announced that its formulation facility at Singapore underwent a USFDA inspection that ended on August 8, 2022. The inspection was completed successfully with Zero 483 observations.

US is one of the key focus markets for Strides and the company has given a growth outlook of US\$250m in FY23 for the US business. The company has set a target to launch ~ 20 new products every year in the US. The company has 279 cumulative ANDA filings (including recently acquired portfolio from Endo at Chestnut Ridge) with USFDA of which 259 ANDAs have been approved and 20 are pending approval. The company has a diversified manufacturing base with 5 USFDA approved facilities which are capable of catering to multiple dosage formats including niche capabilities in controlled Substances, Hormones, Nasal Sprays, Gels, Modified Release products, Liquids.

#### About Strides

Strides, listed on the BSE Limited (532531) and National Stock Exchange of India Limited (STAR), is a global pharmaceutical company headquartered in Bengaluru, India. The Company mainly operates in the regulated markets and has an “in Africa for Africa” strategy along with an institutional business to service donor-funded markets. The Company’s global manufacturing sites are located in India (Chennai, Puducherry and two locations in Bengaluru), Singapore, Italy (Milan), Kenya (Nairobi) and the United States (New York). The Company focusses on “difficult to manufacture” products that are sold in over 100 countries. Additional information is available at the Company’s website at [www.strides.com](http://www.strides.com)

#### For further information, please contact:

##### Strides

##### **Badree Komandur**

Executive Director - Finance & Group CFO  
+91 80 6784 0747

##### Investor Relations

**Sandeep Baid:** +91 80 6784 0791

Email: [Sandeep.baid@strides.com](mailto:Sandeep.baid@strides.com)

##### Strides Pharma Science Limited

CIN: L24230MH1990PLC057062

Regd. Office: 201, 'Devavrata', Sector - 17, Vashi,  
Navi Mumbai - 400 703

Corp. Office: Strides House, Bannerghatta Road,  
Bengaluru – 560 076

##### Corporate Communication

**Pallavi Panchmatia:** +91 80 6784 0193,  
[pallavi.panchmatia@strides.com](mailto:pallavi.panchmatia@strides.com)

##### PR Consultancy

Fortuna PR  
K Srinivas Reddy: +91 90005 27213  
[srinivas@fortunapr.com](mailto:srinivas@fortunapr.com)

Boni Mukherjee: +91 96186 82208  
[boni@fortunapr.com](mailto:boni@fortunapr.com)